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Prion protein and Abeta-related synaptic toxicity impairment
Abstract
Alzheimer's disease (AD), the most common neurodegenerative disorder, goes along with extracellular
amyloid-beta (Abeta) deposits. The cognitive decline observed during AD progression correlates with
damaged spines, dendrites and synapses in hippocampus and cortex. Numerous studies have shown that
Abeta oligomers, both synthetic and derived from cultures and AD brains, potently impair synaptic
structure and functions. The cellular prion protein (PrP(C)) was proposed to mediate this effect. We
report that ablation or overexpression of PrP(C) had no effect on the impairment of hippocampal
synaptic plasticity in a transgenic model of AD. These findings challenge the role of PrP(C) as a
mediator of Abeta toxicity.
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 2010 EMBO Molecular MedicineAlzheimer’s disease (AD), the most common neurodegenerative disorder, goes
along with extracellular amyloid-b (Ab) deposits. The cognitive decline observed
during AD progression correlates with damaged spines, dendrites and synapses in
hippocampus and cortex. Numerous studies have shown that Ab oligomers, both
synthetic and derived from cultures and AD brains, potently impair synaptic
structure and functions. The cellular prion protein (PrPC) was proposed to
mediate this effect. We report that ablation or overexpression of PrPC had no
effect on the impairment of hippocampal synaptic plasticity in a transgenic
model of AD. These findings challenge the role of PrPC as a mediator of Ab
toxicity.
http://dx.doi.org/10.1002/emmm.201000088INTRODUCTION
Alzheimer’s disease (AD) is an age-dependent neurodegenera-
tive disorder that culminates in cognitive decline with limited
treatment options. Oligomeric amyloid-b (Ab), derived from the
b and g cleavage of b-amyloid precursor protein (APP), may
drive AD pathogenesis by activating ill-defined signalling
pathways (Walsh et al, 2005). Several molecules have been
suggested to trigger the latter (De Felice et al, 2009; Shankar
et al, 2007; Snyder et al, 2005). The cellular prion protein (PrPC)
was reported to mediate the impairment of long-term potentiation
(LTP) induced by synthetic Ab oligomers in the hippocampal
Schaffer collateral pathway (Lauren et al, 2009). Also, removal of
PrPC from mice carrying APPswe and PSen1DE9 transgenes
rescued early death and memory impairment (Gimbel et al, 2010).
PrPC is a membrane-anchored glycoprotein (Steele et al,
2007) crucial for axomyelinic integrity of peripheral nerves
(Bremer et al, 2010). The remarkable finding that PrPC mediatesital Zu¨rich, Zu¨rich,
ent of Biology, Brain
Technology, Zu¨rich,
r, Fondazione IRCCS
taly.
þ41 44 635 33 03
þ41-44 255 44 02Ab-related synaptic toxicity was taken to suggest that
interference with PrPC may represent a therapeutic option for
AD (Lauren et al, 2009; Gimbel et al, 2010). However, upon
intracerebral injection of synthetic Ab oligomers, the absence of
PrPC did not prevent deficits in hippocampal dependent
behavioural tests (Balducci et al, 2010).
In view of these conflicting reports, we reasoned that a better
understanding of the impact of PrPC onto AD may come from
careful genetic analyses. Also, the utilization of a second,
independent AD transgenic mouse model may help evaluating
the universality of the observed phenomena. We therefore
asked whether PrPC would modulate the degradation of LTP in
an in vivo model of AD. We crossed mice lacking (Bu¨eler et al,
1992) or overexpressing membrane-anchored (Fischer et al,
1996) or secreted PrP (Chesebro et al, 2005) with APPPS1þ mice
coexpressing mutant APP (APPKM670/671NL) and mutant pre-
senilin-1 (PS1L166P; Radde et al, 2006) which suffer from Ab-
dependent learning and memory deficits (Serneels et al, 2009;
Table 1). We found that ablation or overexpression of PrPC had
no effect on the impairment of hippocampal synaptic plasticity
in a transgenic model of AD. These findings challenge the role of
PrPC as a Ab toxicity mediator.RESULTS AND DISCUSSION
LTP impairment and APP processing are not altered in
absence of the cellular prion protein
We crossed Prnpo/o mice lacking PrPC (Bu¨eler et al, 1992) with
APPPS1þ mice coexpressing mutant APP (APPKM670/671NL) andEMBO Mol Med 2, 306–314 www.embomolmed.org
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Table 1. Genetically modified mice used in this study
Line Description Genetic modifications Genetic background References
APPPS1 Alzheimer’s disease mouse model
displaying Ab42 cerebral amyloidosis
APPKM670/671NL transgene C57BL/6 Radde
et al (2006)PS1L166P transgene (both on Mmu2)
Prnpo/o Mouse lacking cellular prion protein Introduction of a neo cassette replacing PrP codon
4–187 in the Prnp locus in Mmu2 (Prnpo allele)
C57BL/6 and 129/Sv Bu¨eler
et al (1992)
tga20 Mouse overexpressing cellular
prion protein
Introduction of a neo cassette replacing PrP codon
4–187 in the Prnp locus in Mmu2 (Prnpo allele)
C57BL/6 and 129/Sv Fischer
et al (1996)
Prnp minigene on Mmu17
tg44Prnp/ Mouse expressing GPI-anchorless
prion protein
Introduction of a neo cassette into a KpnI site
following residue 93 of PrP in the Prnp locus in
Mmu2 (Prnp allele)
C57BL/10 and 129/Ola Chesebro
et al (2005)
Anchorless PrP transgene
Mmu2 and Mmu17: Mus musculus chromosome 2 and 17, respectively; neo: neomycin phosphotransferase; Prnpo and Prnp denote by convention the ‘Zurich-I’
and ‘Edbg’ knockout alleles of Prnp, respectively.mutant presenilin-1 (PS1L166P; Radde et al, 2006). The resulting
mice did not display any early death independently of the Prnp
genotype (data not shown). High-frequency stimulation (HFS)
of Schaffer collateral CA1 synapses induced an increase in field
excitatory postsynaptic potentials (fEPSP) reflecting LTP in both
4-month-old Prnpþ/þ and Prnpo/o mice (data not shown) as
previously reported (Lledo et al, 1996). In contrast, age-matched
APPPS1þPrnpþ/þ (n¼ 6), APPPS1þPrnpþ/o (n¼ 5) and
APPPS1þPrnpo/o (n¼ 5) all exhibited defective LTP after HFS
(114.23 9.61; 111.72 9.64 and 105.51 12.23%, respec-
tively; p< 0.001; Fig 1A). The fEPSP slopes during the first
2 min were similar in APPPS1þPrnpþ/þ and wild-type mice
(124.1 7.0 and 184.8 26.2%, respectively; p> 0.05), indicat-
ing that immediate post-tetanic potentiation was not affected.
Basal synaptic transmission as assessed by input–output curve
analysis was normal in all mice (Fig 1B and C), confirming
that the APPPS1 transgene induces a selective impairment in
synaptic plasticity. In contrast to 4-month-old animals,
robust LTP was induced in 2-month-old APPPS1þPrnpþ/þ
(172.6 14.6%; n¼ 5), APPPS1þPrnpþ/o (168.9 14%; n¼ 5)
and APPPS1þPrnpo/o mice (204.4 15.9%; n¼ 4) and was
comparable to LTP in Prnpþ/o (174.6 7%; n¼ 5; Fig 1D). We
conclude that the LTP impairment was age related, appeared
only in mice carrying the APPPS1 transgene after >2 months,
and was independent of Prnp gene dosage.
Many genetic polymorphisms affect APP processing and
Ab levels (Lehman et al, 2003). The APPKM670/671NL and
PS1L166P transgenes map to mouse chromosome 2 (Mmu2;
Radde et al, 2006) along with Prnp, and are linked to a
quantitative trait locus that modifies Ab levels (Ryman
et al, 2008). Furthermore, PrPC itself was reported to directly
interfere with APP catabolism (Parkin et al, 2007). Each of
these factors, alone or in combination, may modulate the
production of soluble Ab42, thereby indirectly affecting
LTP impairment. However, we found that 2-month old
gender-matched APPPS1þPrnpþ/þ and APPPS1þPrnpo/o mice
displayed similar levels of APP catabolites (Fig S1A) and soluble
Ab42 (Fig S1B). We conclude that the effects described here
cannot be ascribed to any difference in APP generation or
processing.www.embomolmed.org EMBO Mol Med 2, 306–314Evaluation of genetic confounders that might mask the
impact of PrPC on LTP in 4-month-old APPPS1 mice
A genome-wide screen of 192 polymorphic microsatellites
revealed that APPPS1þPrnpo/o mice contained significantly
larger portions of 129/Sv-derived genome than APPPS1þPrnpþ/þ
mice (129/Sv-specific markers: average SEM: 60 6.2 vs.
2 0.4, respectively; p< 0.001). This genetic constellation
may be taken to suggest that the above intercrosses have
inadvertently introduced genetic biases affecting LTP indepen-
dently of Ab levels (Gerlai, 2002). However, in subsequent
intercrosses, the content in genome-wide 129/Sv-specific mar-
kers was 55.3 3.9 versus 41.7 3.2 (n¼ 7 and 6, respectively;
p< 0.05), yet this statistically significant difference disappeared
upon exclusion of markers on Mmu2 (44.7 3.8 vs. 38.0 3.2,
respectively; p> 0.05). This indicates that the latter mice,
although not inbred, were genetically similar except for the
Mmu2 genomic region that is closely linked to both Prnp and
APPPS1 and does not desegregate easily from these loci by
breeding. This genetic scenario may help explaining the
differences in insoluble Ab42 levels seen in F2 APPPS1
þ mice
with different Prnp genotypes generated by intercrosses of
APPPS1þ and Prnpo/o mice (Fig S2; Ryman et al, 2008).
Transgenic PrPC overexpression disproves Mmu2 bias and
does not aggravate APPPS1-induced LTP impairment
To formally discriminate between PrPC-dependent effect and
potential confounders residing on Mmu2, we reintroduced PrPC
into APPPS1þPrnpo/o mice via crosses to tga20 mice (Fischer et
al, 1996) that carry a Prnp minigene on Mmu17 (Zabel et al,
2009) and overexpress PrPC about fourfold (Fig S3). LTP was
again affected in 4-month-old APPPS1þtga20tg/Prnpo/o
(127.84 12.61%; n¼ 4) and APPPS1þtga20/Prnpo/o litter-
mates (106.56 5.46%; n¼ 5; p¼ 0.137; Fig 2A). The genome-
wide microsatellite patterns of these two groups of mice were
indistinguishable even when Mmu2 markers were included
(129/Sv-specific markers: 61.0 2.1 vs. 61.7 3.9, respectively;
p> 0.05; Fig 2B), indicating that any contribution by genetic
confounders to the phenotype is unlikely. To further explore the
impact of supraphysiological levels on PrPC in LTP, we analyzed
APPPS1þtga20tg/Prnpþ/o which overexpress ca. sevenfold PrPC 2010 EMBO Molecular Medicine 307
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Figure 1. CA1 hippocampal LTP impairment in APPPS1R mice occurs at 4 months of age and is not regulated by PrPC expression.
A. CA1 hippocampal LTP was induced in acute slices from 4-month-old Prnpþ/þ mice (black, n¼ 7), but was abolished in slices from age-matched APPPS1þPrnpþ/þ
(dark blue, n¼ 6), APPPS1þPrnpþ/o (blue, n¼5) and APPPS1þPrnpo/o mice (light blue n¼ 5).
B. fEPSP traces before (red) and after (black) LTP induction. Calibration: 1 mV; 10 ms.
C. Input–output curves (stimulus intensity vs. fEPSP slope) indicative of normal basal synaptic transmission.
D. Unaffected LTP in slices derived from 2-month-old APPPS1þPrnpþ/þ (n¼ 5), APPPS1þPrnpþ/o (n¼ 5), APPPS1þPrnpo/o (n¼4) and Prnpþ/o mice (n¼ 5). These
results indicate that LTP impairment in APPPS1þ mice was not a developmental defect, and occurred only after 2 months of age independently of Prnp gene
dosage.
308(Fig S3) and APPPS1þtga20/Prnpþ/o littermates. These two
groups of mice shared similar genomic microsatellite patterns
(Fig 3A). At 4 months of age, LTP was significantly reduced in
both APPPS1þtga20tg/Prnpþ/o and APPPS1þtga20/Prnpþ/o
littermates (149.41 11.81%, n¼ 6 vs. 121.56 11.65%, respec-
tively; n¼ 4; Fig 3B). Expression of the tga20 allele showed a
tendency towards improved LTP that was not statistically
significant, without altering APP catabolites and soluble and
insoluble Ab42 (Fig 3C and D). Therefore, PrP
C overexpression did
not enhance Ab-mediated LTP impairment; if anything, it may
have marginally antagonized it.
Overexpression of a secreted PrPC variant reduced the
impairment of LTP in 4-month-old APPPS1 mice
We next asked whether a soluble version of PrPC might intercept
Aboligomersand interferewithsynaptic toxicity. Firstweverified 2010 EMBO Molecular Medicinethat interaction of PrPC with Ab species (Balducci et al, 2010;
Lauren et al, 2009) can occur in the absence of PrPC membrane
anchoring. We therefore tested the binding properties of bac-
terially expressed recombinant full-length PrP (recPrP23–230). We
found that recPrP23–230 bound low molecular weight Ab42 species,
and that binding was reduced by monoclonal anti-PrP antibodies
(Polymenidou et al, 2008) raised against its N-proximal region
(Fig S4). Also, we found that a shortened variant of recPrP lacking
the amino-proximal residues 23–121 (recPrP121–230) did not bind
Ab42 (Fig S4). These results confirm that PrP, even when
produced in bacteria and therefore, lacking all eukaryotic post-
translational modifications including the addition of a glycolipid
anchor, can efficiently bind Ab species.
We then crossed APPPS1þPrnpo/o mice to mice expressing
GPI-anchorless PrP (secPrP) which is secreted into body fluids
of tg44Prnp/ transgenic mice (Chesebro et al, 2005). TheEMBO Mol Med 2, 306–314 www.embomolmed.org
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Figure 2. LTP in 4-month-old APPPS1R
mice expressing a PrPC transgene.
A. At 4 months of age, LTP was impaired in
slices from both APPPS1þtga20tg/Prnpo/o
(n¼4) and APPPS1þtga20/Prnpo/o
(n¼5) but not in Prnpþ/þ slices (n¼ 7; LTP
mean SEM from Fig 1A represented as
grey ribbon). Basal synaptic transmission
was normal as indicated by normal input–
output curve (stimulus intensity vs. fEPSP
slope).
B. Average fEPSP slopes (percentage of
baseline) at 10–25 min post-LTP plotted
against the average number of 129/Sv
specific markers for mice depicted in
panel A and Fig 1A. In all investigated
paradigms, LTP suppression by the APPPS1
transgene was independent of the genetic
background.Prnpo and Prnp alleles refer to the ‘Zurich-I’ (Bu¨eler et al, 1992)
and ‘Edbg’ (Manson et al, 1994) gene ablation events. We
measured LTP in hippocampal slices derived from 4-month-old
APPPS1þtg44tg/Prnp/o (n¼ 7) and APPPS1þtg44/Prnp/o
(n¼ 6) littermates with comparable genomic microsatellite
patterns (Fig 4A). Remarkably, secPrP significantly suppressed
the APPPS1-related LTP impairment (151.5 11 and 108.5
7.5%, respectively; p< 0.05, ANOVA and Tukey’s multiple
comparison test, see Fig 4B). The metabolism of APP and the
levels of soluble and insolubleAb42 did not appear to be altered by
the tg44 transgene (Fig 4C and D), suggesting that secPrP exerted
its beneficial effects interfering with the effectors of Ab toxicity.
Despite decades of research, the cascade of events that
originates with the aggregation of Ab and leads up to cognitive
impairment continues to be poorly understood. Many observa-
tions point to a crucial role of transmembrane signaling events
triggered by aggregated Ab. Several membrane proteins have
been reported to bind soluble Ab oligomers—thereby candidat-
ing as potential transducers of toxicity (Deane et al, 2004; De
Felice et al, 2009; Shankar et al, 2007; Snyder et al, 2005; Yan
et al, 1996). A great deal of excitement was generated by the
recovery of PrPC from an expression screen for soluble Ab
oligomer binders, particularly as synthetic soluble Ab oligomers
were found to damage hippocampal LTP in a PrPC-dependentwww.embomolmed.org EMBO Mol Med 2, 306–314manner (Lauren et al, 2009) and impairment of spatial memory
was rescued by genetic ablation of PrP in a mouse model of AD
(Gimbel et al, 2010). However, the report that removal of PrPC
did not prevent the behavioural deficits caused by intracerebral
injection of synthetic Ab oligomers (Balducci et al, 2010)
challenged the role of PrPC as a crucial mediator of Ab
synaptotoxicity.
We crossed mice expressing human Ab to mice lacking or
overexpressing PrPC or a soluble variant thereof to evaluate if
the impact of PrP is persistent also in another AD mouse model
which suffer from Ab-dependent learning and memory deficits
(Serneels et al, 2009). The latter experimental paradigm may
more closely approximate the human disease than the
previously published models (Balducci et al, 2010; Lauren
et al, 2009) as exposure to Ab species is chronic and
uninterrupted over a protracted period, which is arguably more
realistic than hyperacute exposure of brain tissue to Ab.
Furthermore, Ab exists in AD brains as a vastly heterodisperse
spectrum of assemblies ranging from monomers and dimers
to oligomers and extremely large fibrillary aggregates, each
one of which may partly contribute to the AD phenotype (Lesne
et al, 2006; Shankar et al, 2008, 2009; Walsh et al, 2002). As the
relative affinity of the various Ab assemblies for PrPC is not known
in detail, transgenic mice expressing many such assemblies may 2010 EMBO Molecular Medicine 309
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Figure 3. Analysis of 4-month-old APPPS1R mice with supraphysiological levels of PrPC.
A. Percentage of strain-specific microsatellites in APPPS1þtga20tg/Prnpþ/o (n¼ 6) and APPPS1þtga20/Prnpþ/o (n¼ 4) mice is displayed by box plot. No
significant difference in the genetic background of the two mouse strains was detected (Mann–Whitney U-test, two-tailed, p> 0.05).
B. At 4 months of age, slices of both APPPS1þtga20tg/Prnpþ/o (n¼6) and APPPS1þtga20/Prnpþ/o mice (n¼4) displayed reduced LTP when compared to Prnpþ/þ
mice (n¼7); LTP mean SEM from Fig 1A represented as grey ribbon. Basal synaptic transmission was normal as indicated by normal input–output curve
(stimulus intensity vs. fEPSP slope). All error bars: standard errors of the mean.
C. APP expression and processing by secretases were similar in 4-month-old APPPS1þ tga20tg/Prnpþ/o and APPPS1þtga20/Prnpþ/o mice. Left panel:
representative SDS–PAGE followed by immunoblotting using an APP C-terminal antibody detecting full-length APP and ab-CTF; actin was used as loading
control. Right panel: quantitation of chemiluminescence for APP, a-CTF and b-CTF.
D. TRIS-soluble (left panel), detergent-soluble (middle panel) and insoluble (right panel) human Ab42 levels as assessed by ELISA. Each symbol denotes one
individual mouse.
310reveal phenomena that might go unrecognized in simpler systems,
such as application of defined synthetic Ab oligomers.
On the other hand, the genetic crosses described in our study
and in previous work (Gimbel et al, 2010) may suffer from
limitations. PrPC was reported to regulate b-secretase cleavage
(Parkin et al, 2007), and overexpression may interfere with APP
metabolism and Ab levels, thereby indirectly affecting LTP
impairment. Indeed, careful genetic quality control revealed a
mouse-strain dependent effect on insoluble Ab42 levels—a
phenomenon that should be taken into account while
interpreting results from mouse AD models. However, all mice
analyzed in this study displayed similar levels of APP catabolites
and Ab42 independently of Prnp gene dosage. 2010 EMBO Molecular MedicineWe also considered the possibility that potential confounders
residing on Mmu2 might have introduced alterations of the
experimental evaluation (Steele et al, 2007), a problem which
remains unsolved in the study by Gimbel et al. However, in our
paradigm, genome-wide microsatellite analyses and expression
of PrPC from the tga20 minigene on chromosome Mmu17
disproved any Mmu2 bias.
Additionally, one might argue that the exceedingly rapid
amyloid pathology of APPPS1 mice used in our study leads to
irreversible synaptic damage that is independent of Ab
oligomers and, consequently, of PrPC. However, the original
report (Radde et al, 2006) and our observations indicate
that immunohistochemically and biophysically recognizableEMBO Mol Med 2, 306–314 www.embomolmed.org
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Figure 4. Anchorless soluble PrPC reduces hippocampal LTP impairment in APPPS1R mice.
A. Percentage of strain-specific microsatellites in APPPS1þtg44tg/Prnp/o (n¼ 5) and APPPS1þtg44/Prnp/o (n¼5) mice is displayed by box plot. No
significant difference in the genetic background was detected (Mann–Whitney U-test, two-tailed, p>0.05).
B. LTP was induced in slices prepared from 4-month-old tg44tg/Prnp/o (n¼5) and tg44/Prnp/o (n¼ 7) mice, but was impaired in slices from
APPPS1þtg44/Prnp/o mice (n¼6) and partially rescued in APPPS1þtg44tg/Prnp/o (n¼ 7) mice. Basal synaptic transmission was normal as indicated by
normal input–output curve (stimulus intensity vs. fEPSP slope). All mice were compound heterozygotes for the ‘Zurich-I’ (Prnpo) and the ‘Edbg’ (Prnp) knockout
alleles of Prnp.
C. APP expression and processing by secretases were similar in APPPS1þtg44tg/Prnp/o and APPPS1þtg44/Prnp/o mice at 4 months of age. Left panel:
representative SDS–PAGE followed by immunoblotting using an APP C-terminal antibody detecting full-length APP and C-terminal fragments (ab-CTF); actin
was used as loading control. Right panel: quantitation of chemiluminescence revealed no difference in APP, a-CTF and b-CTF between the two groups.
D. TRIS-soluble (left panel), detergent-soluble (middle panel) and insoluble (right panel) human Ab42 levels as assessed by ELISA. Each symbol denotes one
individual mouse.amyloid deposition does not occur in APPPS1 hippocampi
before 4–5 months of age (Fig S5). Therefore, at the time of
our analysis, there was no massive amyloid deposition in the
hippocampus. Furthermore, the rescue of LTP impairment by
secPrP negates the possibility that an overly aggressive
amyloid pathology precludes the evaluation of the role of PrPC
in these mice.
The combined weight of all these results favours the
conclusion that, however enticing, the hypothesis of PrPC being
a crucial mediator of Ab synaptotoxicity might be not universal.www.embomolmed.org EMBO Mol Med 2, 306–314MATERIALS AND METHODS
Mice
To remove the prion protein locus (Prnp), Prnpo/o mice (Bu¨eler et al,
1992) were crossed with APPPS1 mice (Radde et al, 2006).
APPPS1þPrnpo/o or APPPS1 mice were then crossed with tga20tg/
Prnpo/o (Fischer et al, 1996) or tg44tg/Prnp/ mice (Chesebro et al,
2005) to generate the different APPPS1þ and APPPS1 littermate
control mice (Table 1 and Fig S6). The genetic pattern of mouse strains
was determined with a panel of 192 polymorphic microsatellites as 2010 EMBO Molecular Medicine 311
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The paper explained
PROBLEM:
Alzheimer’s disease (AD), the most common neurodegenerative
disorder, culminates in cognitive decline with limited treatment
options. Aggregated Ab, possibly in the form of oligomers,
accumulates in the brain of affected individuals and may drive
AD pathogenesis by activating ill-defined signaling pathways.
The PrPC was reported to mediate the impairment of LTP induced
by synthetic Ab oligomers and removal of PrPC from an AD mouse
model rescued early death and memory deficit. In another study,
however, the absence of PrPC did not prevent deficits in
hippocampal dependent behavioural tests caused by intracer-
ebral injection of Ab oligomers. To investigate the universality of
the observed phenomena, we asked whether PrPC modulates LTP
in a second independent AD mouse model.
RESULTS:
We crossed mice lacking or over-expressing PrPC with APPPS1þ
mice coexpressing mutant APP and mutant presenilin-1, which
suffer from Ab-dependent learning and memory deficits. We
found defective LTP in APPPS1þ mice at 4 months of age. Ablation
or overexpression of PrPC had no effect on this impairment of
hippocampal synaptic plasticity.
IMPACT:
The results reported here suggest that PrPC may not be a
universal mediator of Ab synaptotoxicity. Additional work is
required to refine our understanding of the interaction between
PrPC and Ab and establish whether PrPC is a viable target for
pharmaceutical interventions in AD.
312described (Bremer et al, 2010). All mice were maintained under specific
pathogen-free conditions. Housing and experimental protocols were in
accordance with the Swiss Animal Welfare Law and in compliance with
the regulations of the Cantonal Veterinary Office, Zurich.
Electrophysiology
Hippocampal slice preparation from male mice and fEPSPs recordings
in the CA1 region were as described (Knobloch et al, 2007). The LTP
induction protocol was considered successful, and entered in the
analysis, only if a stable baseline for at least 10min was achieved. To
generate input–output curves, slices were prepared as above and
stimulated every 20 s with increasing intensity (from 0.0 to 0.1mA in
0.01mA increments) using a total of 10 stimuli. For comparing groups,
potentiation of fEPSP slopes during the interval 10–25min post-
tetanus was evaluated. Data points were normalized to the mean
baseline value and expressed as mean SEM All numbers in brackets
indicate analyzed mice; 2–3 slices were typically analyzed for each
mouse.
Tissue preparation
Brain fractionation was performed as described (Shankar et al, 2008)
with modifications. Briefly, snap frozen forebrains were homogenized
in ice-cold tris buffered saline (TBS), after centrifugation at
100,000 g for 1 h the supernatant (called soluble fraction) was
used to determine soluble Ab42. The pellet was homogenized in
phosphate buffered saline plus 0.5% 4-nonylphenyl-polyethylene
glycol (NP40S), 0.5% 3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate (CHAPS) and spun at 16,000 g for 30min. The
resultant supernatant was used to quantify APP, a-C terminal
fragment (CTF) and b-CTF and the remaining pellet was solubilized
in 70% formic acid and insoluble Ab42 was measured after
tris(hydroxymethyl)aminomethane (TRIS)-base neutralization.
Quantification of Ab42 and PrP
C
Levels of Ab42 were assessed by sandwich enzyme-linked immuno-
sorbent assay (ELISA; hAmyloid Ab42, The Genetics Company) 2010 EMBO Molecular Medicineaccording to manufacturer’s instructions. PrPC concentration
was determined by sandwich ELISA as described (Polymenidou et al,
2008).
Immunoblotting
To determine APP and CTFs levels, 20mg of proteins were separated by
electrophoresis on a 4–12% polyacrylamide gel. Primary antibodies
were: anti-APP C-terminal (Sigma) recognizing both mouse and
human APP and CTFs; anti-actin (Chemicon). Protein bands were
detected by adding SuperSignal West Pico Chemiluminescent
Substrate (Pierce) and exposing the blot in a Stella detector (Raytest).
Chemiluminescence quantification was performed by TINA software.
In vitro binding assay
Binding of synthetic human Ab42 (Bachem AG) to immobilized
recombinant PrP (Zahn et al, 1997) was analyzed by ELISA.
Recombinant PrP (recPrP23–231 or recPrP121–231) was immobilized
overnight at 48C on 96-well microtiter plates. Varying concentrations
of synthetic human Ab42 were added to wells and incubated for 1 h.
Bound proteins were detected by incubation with 6E10 antibody
(Covance) followed by horseradish peroxidase-conjugated antimouse
IgG1. Absorbance was measured at 450nm. For Western blot analysis
various concentrations of Ab42 were incubated in the same conditions,
followed by Sodium dodecyl sulphate–polyacrylamide gel electrophor-
esis (SDS–PAGE) and blotting with 6E10 antibody. Binding of human
Ab42 (25 nM) to recPrP23–231 was assessed also in presence of decadic
dilutions (100, 10 and 1nM) of anti-PrP antibodies (Polymenidou
et al, 2008).
Histological analyses
Brains were removed and fixed in 4% formaldehyde in phosphate
buffered saline, pH 7.5, paraffin embedded and cut into 2–4mm
sections. Sections were stained with hematoxylin–eosin (HE) or
antibodies against glial fibrillary acidic protein (GFAP) (DAKO), ionized
calcium binding adapter molecule 1 (Iba1; WAKO) and Ab (4G8;
Signet).EMBO Mol Med 2, 306–314 www.embomolmed.org
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Statistical significance was determined according to one-way ANOVA
followed by Tukey’s post-test for multiple comparison, unpaired Student’s
t-test and Mann–Whitney test using Prism software (GraphPad Soft-
ware). Error bars in the graphs and numbers following the  sign denote
standard errors of the mean unless otherwise indicated.Author contributions
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